Harmony Biosciences Q4 revenue up 21% to $243.8 million; Q4 profit falls
Harmony Biosciences reported fourth quarter and full year 2025 results, with WAKIX net product revenue up 21% in the quarter and 22% for the year. Fourth quarter GAAP net income fell to $22.5 million from $49.5 million, while full year GAAP net income rose to $158.7 million, and the company reiterated 2026 WAKIX net revenue guidance of $1.0 to $1.04 billion.
Key points
- Q4 2025 net product revenue was $243.8 million, compared with $201.3 million in Q4 2024.
- Q4 2025 GAAP net income was $22.5 million, or $0.38 per diluted share, versus $49.5 million, or $0.85, a year earlier.
- Full year 2025 net product revenue was $868.5 million, compared with $714.7 million in 2024; full year GAAP net income was $158.7 million, or $2.71 per diluted share.
- 2026 WAKIX net revenue guidance of $1.0 to $1.04 billion was reiterated.
The filing
Written by AI on Nov 8, 2026, 1:55 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 24, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.